Global Hemophilia Treatment Market Market Companies
- Baxter International, Inc.
- Hospira, Inc.
- Baxalta
- Novo Nordisk
- Biogen Inc.
- Pfizer, Inc.
- Bayer AG
- CSL Behring
- Chugai Pharmaceutical Co.
- Ferring B.V.
- Genentech, Inc.
- Kedrion
- Octapharma AG
- Sanofi SA
- Shire Plc.
- Swedish Orphan Biovitrum AB
Recent News:
- In February 2023, The US Food and Drug Administration (FDA) approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN-ehtl Fusion Protein]. It was formerly known as efanesoctocog alfa, a first-in-class, long-term factor VIII replacement therapy. ALTUVIIIO is the first and only treatment for Hemophilia A that delivers normal to near-normal factor activity levels (above 40%) for most of the week with a once-daily dose. weeks, significantly reducing bleeding compared to previous factor VIII prophylaxis.
- In January 2023, BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, announced positive results after more than three years of follow-up from the GENer8- 1 Global phase 3 is ongoing in ROCTAVIANTM (valoctocogene roxaparvovec). This is a one-time experimental gene therapy intended to treat adults with severe hemophilia A. This is the largest and longest global phase 3 study of any gene therapy for hemophilia, with 134 participants.